“…BCP has been reported to exert protective effects in experimental animal models of inflammatory pain (Gertsch et al, 2008), kidney injury (Horvath et al, 2012b), ischaemic stroke (Choi et al, 2013), Parkinson's disease (Ojha et al, 2016), toxic hepatitis (D-galactosamine-and endotoxin-induced) (Cho et al, 2015), experimental liver fibrosis (Mahmoud et al, 2014) and colitis (Bento et al, 2011). BCP has been also proposed recently, to have anti-addictive potential (Al Mansouri et al, 2014). BCP has been reported to act on targets other than CB 2 receptors, including sirtuin 1 (SIRT-1; Zheng et al, 2013), PPAR-α (Wu et al, 2014), fatty acid amide hydrolase (FAAH) or COX-2 (Chicca et al, 2014).…”